Home LiteratureArticle Details
PMID: 18987181 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels.

Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, Wagner E, Parratt A, Xu J, Li Z, Zaleska MM, Jacobsen JS, Pangalos MN, Reinhart PH

Abstract

Inheritance of the apoE4 allele (epsilon4) increases the risk of developing Alzheimer's disease; however, the mechanisms underlying this association remain elusive. Recent data suggest that inheritance of epsilon4 may lead to reduced apoE protein levels in the CNS. We therefore examined apoE protein levels in the brains, CSF and plasma of epsilon2/2, epsilon3/3, and epsilon4/4 targeted replacement mice. These apoE mice showed a genotype-dependent decrease in apoE levels; epsilon2/2 >epsilon3/3 >epsilon4/4. Next, we sought to examine the relative contributions of apoE4 and apoE3 in the epsilon3/4 mouse brains. ApoE4 represented 30-40% of the total apoE. Moreover, the absolute amount of apoE3 per allele was similar between epsilon3/3 and epsilon3/4 mice, implying that the reduced levels of total apoE in epsilon3/4 mice can be explained by the reduction in apoE4 levels. In culture medium from epsilon3/4 human astrocytoma or epsilon3/3, epsilon4/4 and epsilon3/4 primary astrocytes, apoE4 levels were consistently lower than apoE3. Secreted cholesterol levels were also lower from epsilon4/4 astrocytes. Pulse-chase experiments showed an enhanced degradation and reduced half-life of newly synthesized apoE4 compared with apoE3. Together, these data suggest that astrocytes preferentially degrade apoE4, leading to reduced apoE4 secretion and ultimately to reduced brain apoE levels. Moreover, the genotype-dependent decrease in CNS apoE levels, mirror the relative risk of developing AD, and suggest that low levels of total apoE exhibited by epsilon4 carriers may directly contribute to the disease progression, perhaps by reducing the capacity of apoE to promote synaptic repair and/or Abeta clearance.

MeSH Terms
Analysis of Variance Animals Animals, Newborn Apolipoproteins E/genetics,metabolism Brain/metabolism Cells, Cultured Culture Media, Conditioned/pharmacology DNA Mutational Analysis Dose-Response Relationship, Drug Humans Hydrocarbons, Fluorinated/pharmacology Male Mice Mice, Transgenic Neuroglia/drug effects,metabolism Polymorphism, Genetic RNA, Messenger/metabolism Sulfonamides/pharmacology Time Factors
Chemicals
Apolipoproteins E Culture Media, Conditioned Hydrocarbons, Fluorinated RNA, Messenger Sulfonamides TO-901317
Authors & Affiliations
18 authors, click to expand affiliations / ORCID
Riddell David R
Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA. riddeld@wyeth.com
Zhou Hua
Atchison Kevin
Warwick Helen K
Atkinson Peter J
Jefferson Julius
Xu Lin
Aschmies Suzan
Kirksey Yolanda
Hu Yun
Wagner Erik
Parratt Adrienne
Xu Jane
Li Zhuting
Zaleska Margaret M
Jacobsen J Steve
Pangalos Menelas N
Reinhart Peter H
References (67)
67 references, click to expand
  1. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse.
    Stroke. 1999 May;30(5):1118-24 PMID: 10229753
  2. Apo E structure determines VLDL clearance and atherosclerosis risk in mice.
    J Clin Invest. 1999 Jun;103(11):1579-86 PMID: 10359567
  3. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent.
    Brain Res. 1999 Oct 2;843(1-2):87-94 PMID: 10528114
  4. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.
    N Engl J Med. 2000 Jan 27;342(4):240-5 PMID: 10648765
  5. Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis.
    Neurogenetics. 1998 Mar;1(3):213-6 PMID: 10737125
  6. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities.
    Neuroscience. 2000;101(4):879-84 PMID: 11113336
  7. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.
    Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8838-43 PMID: 11447277
  8. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion.
    Neurobiol Dis. 2001 Aug;8(4):611-25 PMID: 11493026
  9. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
    Neurology. 2001 Sep 11;57(5):853-7 PMID: 11552016
  10. Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E.
    Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11587-91 PMID: 11553788
  11. CNS synaptogenesis promoted by glia-derived cholesterol.
    Science. 2001 Nov 9;294(5545):1354-7 PMID: 11701931
  12. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease.
    J Neurochem. 2002 Apr;81(2):229-36 PMID: 12064470
  13. Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease.
    Neuroscience. 2002;114(4):1103-14 PMID: 12379263
  14. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease.
    J Biol Chem. 2002 Dec 27;277(52):50380-5 PMID: 12393895
  15. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans.
    Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):269-74 PMID: 12588770
  16. Role of cholesterol in synapse formation and function.
    Biochim Biophys Acta. 2003 Mar 10;1610(2):271-80 PMID: 12648780
  17. APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis.
    Exp Neurol. 2003 Sep;183(1):249-53 PMID: 12957508
  18. Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis.
    Mult Scler. 2003 Oct;9(5):476-80 PMID: 14582773
  19. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients.
    Neuroscience. 2003;122(2):305-15 PMID: 14614898
  20. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro.
    J Lipid Res. 1992 Nov;33(11):1677-88 PMID: 1464751
  21. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes.
    J Neurochem. 2004 Feb;88(3):623-34 PMID: 14720212
  22. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.
    Neuron. 2004 Jan 22;41(2):193-202 PMID: 14741101
  23. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.
    J Neurosci. 2004 Mar 10;24(10):2527-34 PMID: 15014128
  24. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice.
    Neuroscience. 2004;124(4):725-33 PMID: 15026113
  25. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4.
    Ann Neurol. 2004 Apr;55(4):563-9 PMID: 15048896
  26. Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux.
    J Biol Chem. 2004 Jun 18;279(25):25966-77 PMID: 15066991
  27. ApoE genotype accounts for the vast majority of AD risk and AD pathology.
    Neurobiol Aging. 2004 May-Jun;25(5):641-50 PMID: 15172743
  28. ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function.
    J Mol Neurosci. 2004;23(3):235-46 PMID: 15181252
  29. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.
    Nat Med. 2004 Jul;10(7):719-26 PMID: 15195085
  30. Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model.
    Hum Mol Genet. 2004 Sep 1;13(17):1959-68 PMID: 15229191
  31. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism.
    Ann N Y Acad Sci. 2004 Jun;1019:24-8 PMID: 15246987
  32. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor.
    J Lipid Res. 2004 Oct;45(10):1929-42 PMID: 15292374
  33. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.
    J Biol Chem. 2005 Feb 11;280(6):4079-88 PMID: 15557325
  34. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease.
    Neurobiol Aging. 2005 Mar;26(3):355-61 PMID: 15639314
  35. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.
    Neurobiol Dis. 2005 Feb;18(1):75-82 PMID: 15649697
  36. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.
    J Neurosci. 2005 Mar 16;25(11):2803-10 PMID: 15772340
  37. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons.
    Stroke. 2005 May;36(5):954-9 PMID: 15774818
  38. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia.
    Mov Disord. 2006 Jan;21(1):45-9 PMID: 16116614
  39. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide.
    Chem Phys Lipids. 2005 Oct;137(1-2):52-61 PMID: 16140289
  40. Effect of domain interaction on apolipoprotein E levels in mouse brain.
    J Neurosci. 2005 Nov 16;25(46):10658-63 PMID: 16291938
  41. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease.
    Neurobiol Dis. 2006 Jun;22(3):555-61 PMID: 16473016
  42. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo.
    J Neurochem. 2006 Aug;98(3):792-800 PMID: 16771834
  43. Apolipoprotein E structure: insights into function.
    Trends Biochem Sci. 2006 Aug;31(8):445-54 PMID: 16820298
  44. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia.
    Arch Neurol. 2007 Feb;64(2):261-5 PMID: 17296843
  45. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.
    Mol Cell Neurosci. 2007 Apr;34(4):621-8 PMID: 17336088
  46. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Acta Neurol Scand. 2008 Jan;117(1):21-5 PMID: 17883422
  47. Protein folding, unfolding and misfolding: role played by intermediate States.
    Mini Rev Med Chem. 2008 Jan;8(1):57-62 PMID: 18220985
  48. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
    J Lipid Res. 1990 Mar;31(3):545-8 PMID: 2341813
  49. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects.
    Clin Genet. 1986 Jun;29(6):477-84 PMID: 3461894
  50. Abnormal in vivo metabolism of apolipoprotein E4 in humans.
    J Clin Invest. 1986 Sep;78(3):815-21 PMID: 3745440
  51. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.
    J Clin Invest. 1985 Oct;76(4):1501-13 PMID: 3932467
  52. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease.
    Trends Neurosci. 1994 Dec;17(12):525-30 PMID: 7532337
  53. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.
    Science. 1994 May 6;264(5160):850-2 PMID: 8171342
  54. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
    Science. 1993 Aug 13;261(5123):921-3 PMID: 8346443
  55. Inhibition of apolipoprotein E degradation in a post-Golgi compartment by a cysteine protease inhibitor.
    J Biol Chem. 1993 Apr 25;268(12):8497-502 PMID: 8473293
  56. Lysosomal degradation and sorting of apolipoprotein E in macrophages.
    J Lipid Res. 1995 Oct;36(10):2129-40 PMID: 8576639
  57. Quantitation of apolipoprotein E.
    Methods Enzymol. 1996;263:170-87 PMID: 8749007
  58. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease.
    Brain Res Mol Brain Res. 1995 Oct;33(1):174-8 PMID: 8774959
  59. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis.
    J Neurol Sci. 1996 Aug;139 Suppl:34-7 PMID: 8899655
  60. Human apolipoprotein E: the Alzheimer's disease connection.
    FASEB J. 1996 Nov;10(13):1485-94 PMID: 8940294
  61. Changes in phenotypes of apolipoprotein E and apolipoprotein(a) in liver transplant recipients.
    Clin Transplant. 1997 Aug;11(4):325-7 PMID: 9267723
  62. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia.
    J Cereb Blood Flow Metab. 1997 Jul;17(7):753-8 PMID: 9270492
  63. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury.
    Neuroscience. 1997 Oct;80(4):1255-62 PMID: 9284075
  64. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice.
    J Cereb Blood Flow Metab. 1998 Apr;18(4):361-6 PMID: 9538900
  65. Nascent astrocyte particles differ from lipoproteins in CSF.
    J Neurochem. 1998 May;70(5):2070-81 PMID: 9572293
  66. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury.
    Exp Neurol. 1998 Jun;151(2):314-25 PMID: 9628766
  67. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury.
    Neurology. 1999 Jan 15;52(2):244-8 PMID: 9932938
Article Info
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
Abbr.
J Neurosci
ISSN
1529-2401
Published
2008-11-05
Pages
11445-53
Language
English
Region
United States
NLM ID
8102140
PMCID
PMC6671315
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com